Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH Pituitary Neuroendocrine Tumor (PitNETs), Mammosomatotrophs, and Mixed Tumors
Authors' conclusion
These findings highlight the heterogeneity within GH&PRL PitNETs, including silent PRL-positive GH PitNETs. Our data suggest mixed SL tumors may be less responsive to SSTR ligands, emphasizing the need for tailored strategies based on tumor subtype and receptor profile.
Study context
- Population
- Patients with acromegaly with PitNETs
- Participants
- 51 PitNETs
- Exposure
- GH PitNETs vs mammosomatotrophs vs mixed SL PitNETs
- GH PitNETsn = 23
- Mammosomatotrophsn = 20
- Mixed SL PitNETsn = 8
- Outcome
- Clinical and molecular differences between subtypes
Methodological detailsdouble immunofluorescence, clinicopathological correlation
- Double immunofluorescence
- Clinicopathological correlation
Main finding
As reported in the abstract
Prolactin (PRL)-positive tumors without hyperprolactinemia (silent PRL-positive GH PitNETs)
41%
Observational data: associations, not effects.
Original publication
Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors. J Clin Endocrinol Metab. Published 26 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →